Skip to main content

Table 7 Long-term changes in serum levels of brain-derived neurotrophic factor (BDNF) in responders at week 24

From: Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial

  Baseline Week 6 Week 12 Week 24 Statistics P
Mature BDNF (ng/mL), EMS (SE) 12.7 (0.7) 11.2 (0.7)a 11.8 (0.7)a 12.1 (0.7) F = 3.5, df = 2.4 0.027*
ProBDNF (pg/mL), median [quartiles] 634.7 [92.4, 5381.8] 507.9 [95.6, 4975.8] 484.5 [82.5, 4471.0] 463.5 [109.5, 4018.4]b χ 2 = 8.5, df = 3 0.036*
Ratio of mature BDNF/proBDNF, median [quartiles] 22.7 [2.1, 135.6] 27.0 [2.3, 115.5] 29.3 [2.7, 127.8] 30.4 [3.1, 153.6] χ 2 = 1.6, df = 3 0.67
  1. Serum mature BDNF levels were analyzed using repeated measure analysis of variance (ANOVA). Adjustment for multiple comparisons was Bonferroni. Serum proBDNF levels and ratio of mature BDNF/proBDNF levels were analyzed using Friedman’s test followed by Wilcoxon signed rank test
  2. BDNF brain-derived neurotrophic factor, EMS estimated marginal means, SE standard error, CI confidence interval
  3. aMean differences in serum mature BDNF levels at week 6 (−1.4 ng/mL, SE = 0.5, 95 % CI −2.7 to –0.07, P = 0.035) and at week 12 (−0.8 ng/mL, SE = 0.3, 95 % CI −1.7 to −0.01, P = 0.045) were significantly decreased compared to the baseline levels
  4. bSerum proBDNF levels at week 24 were significantly decreased compared to the baseline levels (Z = −2.4, P = 0.019). *P < 0.05, n = 27